Clearbridge Investments LLC Has $136.12 Million Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Clearbridge Investments LLC lessened its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 2.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 409,711 shares of the company’s stock after selling 8,194 shares during the quarter. Clearbridge Investments LLC owned about 1.32% of Medpace worth $136,118,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Joseph Group Capital Management raised its position in shares of Medpace by 18.9% in the 4th quarter. Joseph Group Capital Management now owns 3,620 shares of the company’s stock valued at $1,203,000 after acquiring an additional 575 shares during the period. Orion Portfolio Solutions LLC increased its stake in Medpace by 347.6% in the fourth quarter. Orion Portfolio Solutions LLC now owns 4,248 shares of the company’s stock valued at $1,411,000 after purchasing an additional 3,299 shares in the last quarter. New Age Alpha Advisors LLC acquired a new stake in Medpace in the fourth quarter worth $1,886,000. Norges Bank bought a new position in shares of Medpace during the fourth quarter worth $69,859,000. Finally, WINTON GROUP Ltd grew its holdings in shares of Medpace by 43.0% in the 4th quarter. WINTON GROUP Ltd now owns 3,343 shares of the company’s stock valued at $1,111,000 after buying an additional 1,006 shares during the period. Institutional investors own 77.98% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Leerink Partnrs upgraded Medpace to a “hold” rating in a report on Monday, March 24th. Leerink Partners initiated coverage on Medpace in a report on Monday, March 24th. They set a “market perform” rating and a $330.00 price objective on the stock. Finally, Robert W. Baird boosted their price objective on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Nine research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Medpace has an average rating of “Hold” and a consensus target price of $376.30.

Medpace Trading Down 1.3 %

MEDP opened at $312.36 on Monday. The stock’s fifty day simple moving average is $335.90 and its 200 day simple moving average is $339.18. Medpace Holdings, Inc. has a 1-year low of $302.01 and a 1-year high of $459.77. The stock has a market cap of $9.52 billion, a PE ratio of 24.73, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. Equities analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.